肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

DCIS和浸润性乳腺癌的外科手术选择

2011-11-12 MedSci原创 MedSci原创

乳腺癌外科手术
关注

DCIS和浸润性乳腺癌的外科手术选择

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1993585, encodeId=7f2b199358565, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Mar 06 23:59:00 CST 2012, time=2012-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661876, encodeId=092216618e6e9, content=<a href='/topic/show?id=85485e479f' target=_blank style='color:#2F92EE;'>#DCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5747, encryptionId=85485e479f, topicName=DCI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=100e25353151, createdName=ms691033630344116, createdTime=Tue Jul 31 19:59:00 CST 2012, time=2012-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343260, encodeId=d98d1343260a9, content=<a href='/topic/show?id=d3ea4293676' target=_blank style='color:#2F92EE;'>#外科手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42936, encryptionId=d3ea4293676, topicName=外科手术)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Mon Nov 14 14:59:00 CST 2011, time=2011-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461255, encodeId=c06b146125547, content=<a href='/topic/show?id=4ebd65e084e' target=_blank style='color:#2F92EE;'>#浸润性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65708, encryptionId=4ebd65e084e, topicName=浸润性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91ec6409669, createdName=xuyu, createdTime=Mon Nov 14 14:59:00 CST 2011, time=2011-11-14, status=1, ipAttribution=)]
    2012-03-06 12498ebem19暂无昵称

    #CIS#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1993585, encodeId=7f2b199358565, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Mar 06 23:59:00 CST 2012, time=2012-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661876, encodeId=092216618e6e9, content=<a href='/topic/show?id=85485e479f' target=_blank style='color:#2F92EE;'>#DCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5747, encryptionId=85485e479f, topicName=DCI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=100e25353151, createdName=ms691033630344116, createdTime=Tue Jul 31 19:59:00 CST 2012, time=2012-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343260, encodeId=d98d1343260a9, content=<a href='/topic/show?id=d3ea4293676' target=_blank style='color:#2F92EE;'>#外科手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42936, encryptionId=d3ea4293676, topicName=外科手术)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Mon Nov 14 14:59:00 CST 2011, time=2011-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461255, encodeId=c06b146125547, content=<a href='/topic/show?id=4ebd65e084e' target=_blank style='color:#2F92EE;'>#浸润性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65708, encryptionId=4ebd65e084e, topicName=浸润性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91ec6409669, createdName=xuyu, createdTime=Mon Nov 14 14:59:00 CST 2011, time=2011-11-14, status=1, ipAttribution=)]
    2012-07-31 ms691033630344116

    #DCI#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1993585, encodeId=7f2b199358565, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Mar 06 23:59:00 CST 2012, time=2012-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661876, encodeId=092216618e6e9, content=<a href='/topic/show?id=85485e479f' target=_blank style='color:#2F92EE;'>#DCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5747, encryptionId=85485e479f, topicName=DCI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=100e25353151, createdName=ms691033630344116, createdTime=Tue Jul 31 19:59:00 CST 2012, time=2012-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343260, encodeId=d98d1343260a9, content=<a href='/topic/show?id=d3ea4293676' target=_blank style='color:#2F92EE;'>#外科手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42936, encryptionId=d3ea4293676, topicName=外科手术)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Mon Nov 14 14:59:00 CST 2011, time=2011-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461255, encodeId=c06b146125547, content=<a href='/topic/show?id=4ebd65e084e' target=_blank style='color:#2F92EE;'>#浸润性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65708, encryptionId=4ebd65e084e, topicName=浸润性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91ec6409669, createdName=xuyu, createdTime=Mon Nov 14 14:59:00 CST 2011, time=2011-11-14, status=1, ipAttribution=)]
    2011-11-14 ms7524819409032184

    #外科手术#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1993585, encodeId=7f2b199358565, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Mar 06 23:59:00 CST 2012, time=2012-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661876, encodeId=092216618e6e9, content=<a href='/topic/show?id=85485e479f' target=_blank style='color:#2F92EE;'>#DCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5747, encryptionId=85485e479f, topicName=DCI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=100e25353151, createdName=ms691033630344116, createdTime=Tue Jul 31 19:59:00 CST 2012, time=2012-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343260, encodeId=d98d1343260a9, content=<a href='/topic/show?id=d3ea4293676' target=_blank style='color:#2F92EE;'>#外科手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42936, encryptionId=d3ea4293676, topicName=外科手术)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Mon Nov 14 14:59:00 CST 2011, time=2011-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461255, encodeId=c06b146125547, content=<a href='/topic/show?id=4ebd65e084e' target=_blank style='color:#2F92EE;'>#浸润性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65708, encryptionId=4ebd65e084e, topicName=浸润性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91ec6409669, createdName=xuyu, createdTime=Mon Nov 14 14:59:00 CST 2011, time=2011-11-14, status=1, ipAttribution=)]
    2011-11-14 xuyu

    #浸润性乳腺癌#

    0

相关资讯

王永胜：PET/CT在乳腺癌诊治中的应用

　　 　　王永胜教授 　　10月7～9日，由北京大学临床肿瘤学院主办的燕京肿瘤临床与PET/CT应用会议在北京召开。 　　会上，山东省肿瘤医院的王永胜教授结合NCCN指南报告了PET/CT在乳腺癌诊治中的应用。 　　王教授指出，PET/CT对早期乳腺癌淋巴结转移的诊断并不敏感，不适用于临床Ⅰ、Ⅱ或可切除Ⅲ期乳腺癌的分期。在常规分期检查结果难以判断或者存在疑问，特别是在局部晚期或转移性患者中

CSCO 2011:≥4个腋下淋巴结转移乳腺癌患者的局部治疗模式及预后因素分析

　　上海复旦大学附属肿瘤医院乳腺外科/乳腺癌研究所 复旦大学上海医学院肿瘤学系　殷文瑾 柳光宇 狄根红 吴炅 沈镇宙 邵志敏 陆劲松 　　目的：≥4个腋下淋巴结转移的乳腺癌患者具有高危复发风险。大量研究结果已证实，这类患者即使经过积极规范的治疗仍预后较差。然而，目前有关这类患者临床病理学特征的研究却并不多见。因此，本文旨在探究

Breast: 年龄是乳腺癌患者预后不良的独立危险因素

　广州中山大学肿瘤中心学者的一项回顾性病例对照研究共纳入551 例年龄≤35 岁的乳腺癌患者（Ⅰ组），将36~50 岁的乳腺癌患者作为对照（Ⅱ组）。 　　研究结果显示，Ⅰ组患者无病生存（DFS）期、5年DFS率和总生存（OS）率均显著低于Ⅱ组，P 值分别为0.024、＜0.001 和 0.024。多因素分析显示，年龄（≤35岁）是乳腺癌患者预后不

CSCO 2011:中国大陆早期乳腺癌保乳术后放射治疗的全国调查

　中国医学科学院肿瘤医院 张烨 惠周光 余子豪 李晔雄 　　目的：全国早期乳腺癌保乳手术的开展逐渐增加，本研究调查2009年度国内保乳术后放射治疗的实际开展情况。 　　方法：2009年底一份有关保乳术后放射治疗实际开展情况的调查表邮寄至中国大陆的所有登记在中华放射肿瘤学协会的放射治疗单位，对于未回复的单位2010年初再次寄发调查表，并对所有回访的调查表进

NEJM：唑来膦酸辅助疗法不能改善乳腺癌治疗

MedSci点评：本文研究结果显示唑来膦酸辅助疗法不能改善乳腺癌治疗，与以往认识有一些差异。但是本文选择的指标，包括DFS，复发或死亡，均无差异。同时唑来膦酸还会带来一些不良作用。这是大规模研究，结果相当可靠。但是进一步研究，实际上，还可以根据患者的年龄，是否是三阴性乳腺癌等因素进行分层研究，有可能会得出一些不同的结论。 　　罗伯特·E·科尔曼等 AZURE试验研究者 　　背景&nb

NEJM：在HER2阳性乳腺癌中的曲妥珠单抗辅助治疗

　　丹尼斯·斯拉门（Slamon）等 乳腺癌国际研究组成员 　　背景 在人类表皮生长因子受体（HER）阳性乳腺癌的辅助治疗中，曲妥珠单抗可改善（患者的）生存情况，尽管采用基于蒽环类联合疗法的方案与心脏毒性相关。我们想对一种新的含曲妥珠单抗的非蒽环类治疗方案的有效性和安全性进行评估。 　　方法 我们将3222名有HER2阳性早期乳腺癌的妇女随机分为3组：第一组接受多